BlackRock (NYSE: BLK) reports 7.8% beneficial stake in Sagimet Biosciences (SGMT)

BlackRock, Inc. has disclosed a 7.8% beneficial ownership stake in Sagimet Biosciences Inc. (SGMT) Class A Stock, as reported in a Schedule 13G filing. As of June 30, 2026, BlackRock's business units beneficially owned 4,751,186 shares and held sole voting power over 4,690,270 shares. No single BlackRock client holds more than 5% of Sagimet's outstanding common shares.